What do systematic reviews say?

Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Very low

Autologous blood or PRP vs placebo at 3 months' follow‐up

It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).

• Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain 2021 · Cochrane Headline outcomes only
  RR 0.32 [0.03, 2.92]
  1 study · 80 participants
  Very low

Oral viscous budesonide vs swallowed fluticasone

Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.98 [0.42, 2.32]
  1 study · 129 participants
  Low

All doses of cerivastatin vs placebo

It is very uncertain whether all doses of cerivastatin changes withdrawals due to adverse events compared with placebo (very low certainty).

• Cerivastatin for lowering lipids 2020 · Cochrane Headline outcomes only
  RR 1.09 [0.68, 1.74]
  11 studies · 6570 participants
  Very low

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Infliximab vs biosimilar

Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).

• Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
  RR 20.73 [2.86, 150.33]
  1 study · 155 participants
  Low

Naftopidil vs Eviprostat (phytotherapy)

It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found